Entropy NeurodynamicsASX:ENP -3.23% PB Ratio is 6.00 as of Jun. 25, 2026, which is 362% above its 10-year median of 1.30. The stock has 5 warning signs investors should review. Among 1,233 Biotechnology companies, Entropy Neurodynamics ranks worse than 76.4% on this metric.
Entropy Neurodynamics Ltd stock PB Ratio (=6) is close to 5-year high of 6.
The historical rank and industry rank for Entropy Neurodynamics's PB Ratio or its related term are showing as below:
ASX:ENP'
s PB Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.3 Max: 6.2
Current: 6
During the past 7 years, Entropy Neurodynamics's highest PB Ratio was 6.20. The lowest was 0.16. And the median was 1.30.
ASX:ENP's PB Ratio is ranked worse than 76.4% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs ASX:ENP: 6.00
During the past 12 months, Entropy Neurodynamics's average Book Value Per Share Growth Rate was 66.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -75.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -48.80% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Entropy Neurodynamics was -4.20% per year. The lowest was -75.30% per year. And the median was -26.30% per year.
Back to Basics: PB Ratio
Entropy Neurodynamics (ASX:ENP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entropy Neurodynamics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Entropy Neurodynamics (ASX:ENP) has a PB Ratio of 6.00 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Entropy Neurodynamics and its competitors. This is 362% above median its historical median of 1.30. Over the past decade, Entropy Neurodynamics' PB Ratio has ranged from 0.16 to 6.20. According to the industry distribution chart, Entropy Neurodynamics ranks #942 out of 1233 companies in the Biotechnology industry, placing it in the top 76.4%.
Is Entropy Neurodynamics' PB Ratio too high?
Entropy Neurodynamics' current PB Ratio of 6.00 is 362% above median its 10-year median of 1.30. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 6.20. The Biotechnology industry median PB Ratio is 2.83. Entropy Neurodynamics' value of 6.00 is 112% above this industry median. Based on the distribution chart, Entropy Neurodynamics ranks #942 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Entropy Neurodynamics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #942 out of 1233 companies for PB Ratio. This places Entropy Neurodynamics in the lower half of its industry. The industry median PB Ratio is 2.83. Entropy Neurodynamics' value of 6.00 is 112% above this benchmark. Historically, Entropy Neurodynamics' own PB Ratio has ranged from 0.16 to 6.20 over the past decade. While the company's 10-year median is 1.30 vs. the industry median of 2.83, Entropy Neurodynamics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entropy Neurodynamics's current PB Ratio of 6.00 is 112% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Entropy Neurodynamics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current PB Ratio is 6.00, which is 362% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.03 — trading right at its estimated fair value. The current PB Ratio is 6.00, which is 362% above median its 10-year median of 1.30 and 112% above the Biotechnology industry median of 2.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current PB Ratio is 6.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ENP has been successfully added to your 